Tyrosine Kinase Inhibitors for the Elderly
Wolfgang Hohenforst‐Schmidt, Paul Zarogoulidis, Michael Steinheimer, Naim Benhassen, Theodora Tsiouda, Sofia Baka, Lonny B. Yarmus, Grigoris K. Stratakos, John Organtzis, Athanasia Pataka, Kosmas Tsakiridis, Ιlias Karapantzos, Chrysanthi Karapantzou, Kaid Darwiche, Athanasios Zissimopoulos, Georgia Pitsiou, Paul Zarogoulidis, Yan-Gao Man, Harald Rittger · Journal of Cancer · 2016
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · review · 2016
Abstract
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient. The side effects of these agents are still severe for several patients. In the recent years further investigation of the cancer genome has led to targeted therapies. There have been numerous publications regarding novel agents such as; erlotinib, gefitinib and afatinib.
In specific populations these agents have demonstrated higher efficiency and this observation is explained by the overexpression of the EGFR pathway in these populations. We suggest that TKIs should administered in the elderly, and with the word elderly we propose the age of 75. The treating medical doctor has to evaluate the performance status of a patient and decide the best treatment in several cases indifferent of the age. TKIs in most studies presented safety and efficiency and of course dose modification should be made when necessary. Comorbidities should be considered in any case especially in this group of patients and the treating physician should act accordingly.
Open the resolved locator · 10.7150/jca.14819
Metadata licence: OpenAlex metadata (CC0)